Skip to main content
. 2020 May 13;156(7):1–9. doi: 10.1001/jamadermatol.2020.1141

Table 2. Risk Factors for Cutaneous SCC Among 9793 Lung Transplants.

Characteristic AHR (95% CI)a
Sex
Female 1 [Reference]
Male 2.01 (1.73-2.32)
Age at transplant per categoryb 1.54 (1.44-1.65)
Indication for transplant
Chronic obstructive pulmonary disease 1 [Reference]
Idiopathic pulmonary fibrosis 1.44 (1.23-1.69)
Otherc 1.28 (1.05-1.55)
Smoking history
No 1 [Reference]
Yes 1.28 (1.10-1.49)
Daily mean annual ambient UVR, mW/m2
<26.00 1 [Reference]
26.00-31.99 0.94 (0.79-1.13)
32.00-46.99 0.94 (0.79-1.12)
≥47.00 1.11 (0.94-1.32)
Transplant No.
First 1 [Reference]
Second or greater 2.49 (1.92-3.23)
Duration of voriconazole used
No use 1 [Reference]
1-3 mo 1.09 (0.90-1.31)
4-7 mo 1.42 (1.16-1.73)
8-15 mo 2.04 (1.67-2.50)
>15 mo 3.05 (2.37-3.91)
Ever itraconazole use
No 1 [Reference]
Yes 1.20 (1.00-1.45)
Unknown 0.94 (0.73-1.21)
Ever posaconazole use
No 1 [Reference]
Yes 1.08 (0.83-1.39)
Unknown 1.02 (0.75-1.40)
Ever other antifungal usee
No 1 [Reference]
Yes 1.10 (0.89-1.36)
Unknown 1.32 (0.98-1.76)

Abbreviations: AHR, adjusted hazard ratio; SCC, squamous cell carcinoma; UVR, UV radiation.

a

Cox proportional hazards regression models are adjusted for all variables in the table. The baseline hazard was stratified by calendar year of transplantation (2007-2008, 2009-2010, 2011-2012, 2013-2014, and 2015-2016).

b

Categorized as an ordinal variable corresponding to the following ranges: less than 30, 30 to 39, 40 to 49, 50 to 59, 60 to 69, and older than 69 years.

c

Includes cystic fibrosis, other obstructive lung diseases, inflammatory and fibrotic lung, airway diseases, pulmonary hypertension and pulmonary vascular diseases, and other or unspecified conditions.

d

Assessed in 30-day increments; duration of use categories correspond to approximately less than the 33rd, 33rd to 66th, 66th to 90th, and greater than 90th percentiles.

e

Includes fluconazole, amphotericin B, caspofungin acetate, micafungin sodium, anidulafungin, and isavuconazonium sulfate.